Brief Report: Virologic and Immunologic Outcomes for HIV Patients With Coronavirus Disease 2019
Overview
Authors
Affiliations
Background: To describe the virologic and immunologic outcomes among people living with HIV (PLHIV) coinfected with SARS-CoV-2.
Setting: Wuhan, China.
Methods: Thirty-five coinfected patients were identified by matching the reported cases in National Notifiable Infectious Disease Report system for COVID-19 and HIV in Wuhan by time of April 19, 2020. Questionnaire-based survey and follow-up with blood sample collection were used to obtain characteristics before COVID-19 and after recovery. Nonparametric Mann-Whitney U test, χ2, or Fisher exact test, Mcnemar test, and Wilcoxon test were conducted.
Results: Twenty of the 35 coinfected patients were identified as asymptomatic/mild/moderate COVID-19 (nonsevere group) and 15 were identified as severe/critical (severe group). The severe and nonsevere group had no differences in demographics, HIV baseline status, the intervals between last tests and follow-up tests for CD4+ cell count and HIV-1 viral load (all P > 0.05). Overall, there was a significantly increased number of coinfected patients with HIV-1 viral load ≥20 copies/mL after recovery (P = 0.008). The median viral load increased significantly after recovery in severe group (P = 0.034), whereas no significant change of HIV-1 viral load was observed in the nonsevere group. Limited change of CD4+ cell count was found (all P > 0.05).
Conclusion: The coinfection of SARS-CoV-2 may put PLHIV at greater risk for HIV-1 viral rebound especially for severe/critical COVID-19, whereas it had limited impacts on CD4+ cell count. Whether continuous antiretroviral therapy against HIV infection would have significant impacts on CD4+ cell count among PLHIV coinfected with SARS-CoV-2 needs further research.
Bokharaei-Salim F, Khanaliha K, Monavari S, Kiani S, Tavakoli A, Jafari E Curr HIV Res. 2024; 22(1):53-64.
PMID: 38310469 DOI: 10.2174/011570162X273321240105081444.
Qu M, Song B, Yang B, Wang Z, Yu M, Zhang Y Viruses. 2023; 15(12).
PMID: 38140668 PMC: 10748120. DOI: 10.3390/v15122427.
Immune response to BNT162b2 SARS-CoV-2 vaccine in patients living with HIV: The COVIH-DAPT study.
Manni S, Ruetsch C, Fabre R, Ticchioni M, Graca D, Pradier C Front Immunol. 2023; 14:1136723.
PMID: 36949938 PMC: 10025349. DOI: 10.3389/fimmu.2023.1136723.
du Bruyn E, Stek C, Daroowala R, Said-Hartley Q, Hsiao M, Schafer G Nat Commun. 2023; 14(1):188.
PMID: 36635274 PMC: 9836341. DOI: 10.1038/s41467-022-35689-1.
Shah G, Etheredge G, Smallwood S, Maluantesa L, Waterfield K, Ikhile O South Afr J HIV Med. 2022; 23(1):1421.
PMID: 36353191 PMC: 9634654. DOI: 10.4102/sajhivmed.v23i1.1421.